Skip to main content

Glenmark receive US FDA approval for generic Dovonex cream, 0.005%

 

Clinical courses

Glenmark Pharmaceuticals Inc., USA (Glenmark) get final approval by the United States Food & Drug Administration (FDA) for calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 per cent of Leo Pharma A/S.  Glenmark strategy to start to shipping of calcipotriene cream, 0.005 per cent immediately.

Glenmark’s current portfolio contains 98 products authorized for distribution in the US marketplace and 67 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.Glenmark Pharmaceuticals Incis a research-driven, global, integrated pharmaceutical company.